New reports on a plausible link between AstraZeneca’s COVID vaccine and rare blood clotting issues in adults have prompted the Indian government to investigate on the case as the country is now counting on vaccinations to help contain its recent surge in COVID-19 cases.
A government panel of experts has decided to probe for any domestic cases of blood clotting, even mild ones, as a side effect of the two COVID-19 vaccines being administered in India, said a media report. The move by the national committee on adverse effects following immunisation (AEFI) has come after the European’s regulator said it found rare cases of blood clots among some adult recipients who were given AstraZeneca-Oxford university’s vaccine shots.
India is currently administering AstraZeneca’s Covid-19 vaccine, which is manufactured by the Serum Institute and branded Covishield, and a shot developed by Bharat Biotech called Covaxin.
“We are looking at side-effects of blood clots that have been seen in people who received Covishield and Covaxin, even if it was a mild case,” a source told Mint.
Following Europe’s announcement, several countries have announced restrictions on the use of the AstraZeneca vaccine in younger people.